Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EBTC
2526
DELISTED
Enterprise Bancorp
EBTC
| $1.02M | ﹤0.01% |
42,700
-13,500
| -24% | -$313K |
|
|
NE
2527
DELISTED
Noble Corporation
NE
| $1.02M | ﹤0.01% |
3,165,522
+1,554,985
| +97% | +$399K |
|
2528
Fuel Tech
FTEK
$45.6M
| $1.01M | ﹤0.01% |
1,206,638
+15,100
| +1% | +$10.5K |
|
2529
American Vanguard Corp
AVD
$62.8M
| $1.01M | ﹤0.01% |
73,525
-115,364
| -61% | -$1.55M |
|
2530
Cellectar Biosciences
CLRB
$20.9M
| $1.01M | ﹤0.01% |
2,635
+1,861
| +240% | +$781K |
|
2531
MVB Financial
MVBF
$400M
| $1.01M | ﹤0.01% |
76,101
+15,701
| +26% | +$211K |
|
2532
Assured Guaranty
AGO
$3.37B
| $1.01M | ﹤0.01% |
41,410
-169,790
| -80% | -$4.63M |
|
|
WPG
2533
DELISTED
Washington Prime Group Inc.
WPG
| $1.01M | ﹤0.01% |
+133,320
| New | +$979K |
|
|
NAK
2534
Northern Dynasty Minerals
NAK
$930M
| $1M | ﹤0.01% |
+703,604
| New | +$651K |
|
2535
Vanguard Health Care ETF
VHT
$18.9B
| $1M | ﹤0.01% |
+5,200
| New | +$976K |
|
|
OYST
2536
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $1M | ﹤0.01% |
+34,700
| New | +$1.05M |
|
2537
Pro-Dex
PDEX
$215M
| $999K | ﹤0.01% |
56,060
+18,206
| +48% | +$323K |
|
2538
Fortune Brands Innovations
FBIN
$5.73B
| $998K | ﹤0.01% |
18,259
-124,490
| -87% | -$5.79M |
|
|
CYPH
2539
Cypherpunk Technologies Inc
CYPH
$70.1M
| $998K | ﹤0.01% |
47,750
+30,470
| +176% | +$653K |
|
|
NUVA
2540
DELISTED
NuVasive, Inc.
NUVA
| $996K | ﹤0.01% |
17,888
+1,388
| +8% | +$80.3K |
|
2541
Paylocity
PCTY
$7.88B
| $992K | ﹤0.01% |
+6,800
| New | +$791K |
|
|
RBCN
2542
DELISTED
Rubicon Technology, Inc.
RBCN
| $992K | ﹤0.01% |
122,127
+1,523
| +1% | +$11.9K |
|
|
SMTX
2543
DELISTED
SMTC Corporation
SMTX
| $991K | ﹤0.01% |
327,033
-23,400
| -7% | -$68.7K |
|
|
SEEL
2544
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $989K | ﹤0.01% |
255
-26
| -9% | -$86.3K |
|
|
AXLA
2545
DELISTED
Axcella Health Inc. Common Stock
AXLA
| $989K | ﹤0.01% |
+7,152
| New | +$875K |
|
2546
Tiziana Life Sciences
TLSA
$137M
| $987K | ﹤0.01% |
+384,096
| New | +$705K |
|
|
NAVB
2547
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
| $981K | ﹤0.01% |
+249,000
| New | +$476K |
|
2548
Peoples Bancorp of North Carolina
PEBK
$239M
| $979K | ﹤0.01% |
55,396
+653
| +1% | +$11.6K |
|
|
CADE
2549
DELISTED
Cadence Bancorporation
CADE
| $979K | ﹤0.01% |
110,547
-260,100
| -70% | -$1.86M |
|
|
MTSC
2550
DELISTED
MTS Systems Corp
MTSC
| $977K | ﹤0.01% |
55,518
-197,700
| -78% | -$3.65M |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.